Hui-Li Lin Selected Research

eugenosedin-A

4/2021	The effectiveness comparisons of eugenosedin-A, glibenclamide and pioglitazone on diabetes mellitus induced by STZ/NA and high-fat diet in SHR.
3/2018	Eugenosedin-A improves glucose metabolism and inhibits MAPKs expression in streptozotocin/nicotinamide-induced diabetic rats.
3/2014	Eugenosedin-A ameliorates hyperlipidemia-induced vascular endothelial dysfunction via inhibition of α1-adrenoceptor/5-HT activity and NADPH oxidase expression.
2/2013	Eugenosedin-A prevents high-fat diet increased adhesion molecules through inhibition of MAPK- and p65-mediated NF-κB pathway in rat model.
6/2011	Suppression of inflammatory response and endothelial nitric oxide synthase downregulation in hyperlipidaemic C57BL/6J mice by eugenosedin-A.
4/2009	Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hui-Li Lin Research Topics

Disease

5	Inflammation (Inflammations) 05/2022 - 06/2011
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/2021 - 05/2017
4	Atherosclerosis 01/2021 - 02/2007
4	Hyperglycemia 01/2020 - 01/2015
4	Hyperlipidemias (Hyperlipidemia) 01/2020 - 03/2014
3	Fibrosis (Cirrhosis) 05/2022 - 01/2020
3	Body Weight (Weight, Body) 03/2018 - 04/2009
2	Diabetes Mellitus 04/2021 - 03/2018
2	Insulin Resistance 01/2021 - 01/2018
2	Hypoxia (Hypoxemia) 01/2021 - 01/2020
2	Neoplasms (Cancer) 01/2020 - 03/2013
2	Necrosis 01/2020 - 06/2011
2	Weight Gain 01/2019 - 04/2009
2	Obesity 06/2011 - 04/2009
1	Non-alcoholic Fatty Liver Disease 05/2022
1	Hypertrophy 05/2022
1	Hypertriglyceridemia 05/2022
1	Hyperuricemia 05/2022
1	Myocardial Infarction 01/2022
1	Infarction (Infarctions) 01/2022
1	Tachycardia (Tachyarrhythmias) 04/2021
1	Hypertension (High Blood Pressure) 04/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Pathologic Neovascularization 01/2021
1	Thrombosis (Thrombus) 01/2021
1	Overweight 01/2020
1	Rheumatoid Arthritis 09/2014
1	Autoimmune Diseases (Autoimmune Disease) 09/2014
1	Hyperinsulinism (Hyperinsulinemia) 03/2014
1	Carcinogenesis 03/2013
1	Neoplasm Metastasis (Metastasis) 03/2013
1	Carcinoma (Carcinomatosis) 03/2013
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/2011
1	Hepatocellular Carcinoma (Hepatoma) 01/2010

Drug/Important Bio-Agent (IBA)

7	Proteins (Proteins, Gene)FDA Link 05/2022 - 06/2011
7	Glucose (Dextrose)FDA LinkGeneric 04/2021 - 04/2009
6	LipidsIBA 05/2022 - 01/2008
6	eugenosedin-AIBA 04/2021 - 04/2009
6	Insulin (Novolin)FDA Link 01/2019 - 04/2009
3	Interleukin-6 (Interleukin 6)IBA 05/2022 - 01/2020
2	Neuropeptide YIBA 01/2021 - 01/2021
2	gamma-oryzanolIBA 01/2020 - 01/2019
2	Dinoprostone (PGE2)FDA Link 01/2020 - 06/2011
2	FlavonoidsIBA 05/2019 - 01/2019
2	Insulin ReceptorIBA 01/2019 - 01/2015
2	Blood Glucose (Blood Sugar)IBA 03/2018 - 03/2014
2	Messenger RNA (mRNA)IBA 09/2014 - 06/2011
2	CholesterolIBA 03/2014 - 02/2013
1	FructoseIBA 05/2022
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	Glyburide (Glibenclamide)FDA LinkGeneric 04/2021
1	Pioglitazone (Actos)FDA Link 04/2021
1	Adrenergic Agents (Adrenergic Drugs)IBA 04/2021
1	Nicotine FDA Link 01/2021
1	U 0126 (UO 126)IBA 01/2020
1	CytokinesIBA 01/2020
1	Transcription Factor RelAIBA 01/2020
1	Small Interfering RNA (siRNA)IBA 01/2020
1	ElementsIBA 01/2019
1	Dietary Fiber FDA Link 01/2019
1	Bile Acids and Salts (Bile Acids)IBA 01/2019
1	Oxidoreductases (Dehydrogenase)IBA 01/2019
1	Anthocyanins (Anthocyanin)IBA 01/2019
1	LDL Receptors (LDL Receptor)IBA 01/2019
1	Aminobutyrates (Aminobutyric Acid)IBA 01/2019
1	Stearoyl-CoA DesaturaseIBA 01/2019
1	SterolsIBA 01/2019
1	Fatty Acid Synthases (Fatty Acid Synthase)IBA 01/2019
1	Proprotein Convertase 9IBA 01/2019
1	3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)IBA 01/2019
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2019
1	oxidized low density lipoproteinIBA 01/2019
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2019
1	AdiponectinIBA 01/2019
1	AMP-Activated Protein KinasesIBA 01/2019
1	Insulin Receptor Substrate ProteinsIBA 01/2019
1	GlucokinaseIBA 01/2019
1	gamma-Aminobutyric Acid (GABA)IBA 01/2019
1	Niacinamide (Nicotinamide)FDA LinkGeneric 03/2018
1	Streptozocin (Streptozotocin)FDA Link 03/2018
1	Estrogens (Estrogen)FDA Link 09/2014
1	LDL Lipoproteins (beta Lipoproteins)IBA 03/2014
1	HDL LipoproteinsIBA 03/2014
1	Triglycerides (Triacylglycerol)IBA 03/2014
1	ChemokinesIBA 03/2014
1	NADPH Oxidases (NAD(P)H oxidase)IBA 03/2014
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 03/2014
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 03/2014
1	Adrenergic Receptors (Adrenergic Receptor)IBA 03/2014
1	Adrenergic Antagonists (Antiadrenergic Agents)IBA 02/2013
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 06/2011
1	NitratesIBA 06/2011
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 06/2011
1	InterferonsIBA 06/2011
1	Atorvastatin (Lipitor)FDA Link 06/2011
1	CalcineurinIBA 04/2011
1	Estradiol (Delestrogen)FDA LinkGeneric 04/2011
1	Estrogen Receptor alphaIBA 04/2011

Therapy/Procedure

1	Therapeutics 01/2022
1	Drug Therapy (Chemotherapy) 01/2010